More than 60% of all pharmaceutical target proteins and the majority of all new pharmaceuticals and vaccines, are protein-based. In research and development, and production of these protein-based therapeutics, finding the optimal conditions for protein production is often a time-consuming and laborious process. Xbrane Biopharma has two tightly-controlled bacterial protein expression systems. They enable expression of host-toxic and challenging proteins, as well as high yields of soluble proteins.
Xbrane Biopharma
Xbrane Biopharma aims to take protein production in E. coli to the next level. The company enables their customers to produce their proteins in a controllable system, with higher yields and better quality.
